In a new article, Lif argues that Sweden still lacks a unified, national vaccination program for adults, despite having a long-standing and well-functioning childhood vaccination program.

Key points highlighted:

• Vaccination is described as one of the most effective public health measures, saving lives, reducing suffering, and easing the burden on healthcare.

• For adults, the article says responsibility, recommendations, and access become unclear, which leads to many missing vaccinations they could benefit from.

• The article links adult vaccination to healthier ageing, and to reduced need for antibiotics, supporting efforts to slow antibiotic resistance.

• A national program is presented as a way to create clarity on which vaccines are recommended, when they should be taken, and how they are offered.

• It also argues this could support more equal care, so access is not determined by where someone lives.

The piece concludes that new, more effective vaccines are developing quickly, and that systems need to keep pace.

Read more at https://www.lif.se/nyheter/2026/4/att-forebygga-ar-att-ta-ansvar–nu-behovs-ett-vaccinationsprogram-for-vuxna/

Indlægget Sweden lacks a national adult vaccination program blev først udgivet på NHTA.

The Danish Association of the Pharmaceutical Industry, LIF, highlights a new report from EFPIA arguing that investing in prevention, early detection and effective treatment can improve outcomes while strengthening public finances.

What the report highlights

• Five major chronic diseases (cardiovascular disease, diabetes, COPD, stroke and breast cancer) are estimated to cost the EU over €530 billion per year, more than 3% of GDP.

• Much of today’s spending is described as going to treating consequences rather than avoiding disease.

• The report points to potential positive returns: for each euro invested in better prevention and treatment, society may receive a positive payback in some cases.

Examples cited

• Earlier bowel cancer diagnosis is associated with survival increasing from 10% (stage 4) to 90% (stage 1) and costs estimated to be 2.6x lower.

• Scaling treatment for cardiovascular disease, diabetes and breast cancer is estimated to deliver a return on investment of €1.1–€4.9 per €1 invested.

Read more at https://www.lif.dk/ny-rapport-sundhed-er-en-investering-ikke-en-udgift/

Indlægget EFPIA: Invest early in health to save later blev først udgivet på NHTA.